TABLE 1.
Patient Characteristics
| Characteristic | Center 1 | Center 2 | Center 3 | P |
| No. of patients | 13 | 14 | 5 | |
| Age (y) | 69 (52–88) | 65 (47–75)* | 69 (64–77) | 0.05* |
| Length (cm) | 176 (165–185) | 184 (164–194)* | 172 (164–177) | 0.03* |
| Weight (kg) | 83 (66–122) | 88 (65–125) | 90 (68–106) | 0.88 |
| Gleason score | 8 (7–10) | 8 (5–10) | 7.5 (6–9) | 0.31 |
| PSA (ng/mL) | 4.9 (0.5–1,298)† | 103 (11–1,602) | 107 (15–436) | 0.001† |
| Lesion (n) | 0.06‡ | |||
| Bone | 36 | 62 | 21 | |
| Lymph node | 6 | 13 | 9 | |
| Soft tissue | 2 | 0 | 0 | |
| Location (n) | 0.99‡ | |||
| Skull | 1 | 2 | 0 | |
| Cervical vertebrae | 2 | 5 | 2 | |
| Thoracic vertebrae | 4 | 7 | 2 | |
| Lumbar vertebrae | 5 | 8 | 2 | |
| Sacral vertebrae | 4 | 9 | 2 | |
| Pelvis | 6 | 7 | 2 | |
| Ribs/sternum/clavicles | 10 | 17 | 7 | |
| Extremities | 4 | 7 | 2 | |
| Pelvic | 2 | 6 | 6 | |
| Upper abdominal | 1 | 2 | 2 | |
| Thoracic | 3 | 3 | 0 | |
| Neck | 2 | 2 | 2 | |
| Scanner type | GE 690 or GE710 | Philips Gemini TF 64 | Philips Ingenuity TF 128 | |
| Uptake time (min) | ||||
| Test | 46 (36–53) | 45 (45–47)§ | 60 (42–60) | 0.06 |
| Retest | 47 (38–59) | 45 (44–48)§ | 60 (57–67)‖ | 0.00‖ |
| Injected activity (MBq) | ||||
| Test | 306 (241–348) | 194 (152–216)* | 309 (234–319) | 0.00* |
| Retest | 323 (298–355) | 193 (186–215)* | 295 (251–333) | 0.00* |
| Residual dose (MBq) | ||||
| Test | 16.4 (5.85–30.7) | 36.5 (26.0–62.5)* | 16.1 (14.4–31.8) | 0.00* |
| Retest | 15.7 (6.68–28.7) | 35.9 (18.4–53.5)* | 20.5 (14.1–24.8) | 0.00* |
*
Significant difference between sites (1-way ANOVA).
†
Prostate-specific antigen (PSA) levels were significantly lower for Center 1 (Kruskal–Wallis test).
‡
χ2 test.
§
Variability was significantly different from other 2 sites (Levene test).
‖
Uptake time was significantly longer for Center 3 (Kruskal–Wallis test).
Data are median, with range given in parentheses.